A SUPPLY CHAIN CRISIS STORY: CULTURE BAG SHORTAGE ENFORCED VALIDATION OF AN ALTERNATIVE EXPANSION SYSTEM FOR CAR T CELLS

Overview
Due to supply chain shortages, the authors validated G-Rex® vessels as an alternative to Wave bioreactors for CAR T expansion. G-Rex® 1L vessels produced 2-4 billion T cells with >90% viability and comparable phenotype/function, using significantly less media and labor than the Wave system.
What this paper found
G-Rex® vessels were validated as a replacement for Wave bioreactor culture bags to manufacture lentiviral CAR T cells when bag supply ran short. Mesothelin CAR T cells from consented patient material were produced in parallel in G-Rex® and Wave systems. G-Rex® products showed lower transduction efficiency at the same multiplicity of infection, yet expansion was at least 50-fold, viability exceeded 90%, and phenotypes were comparable. Cells from both processes mediated CAR-dependent cytotoxicity and cytokine production. A 1 L G-Rex® seeded with 50 million T cells yielded 2-4 billion cells, using one third of the starting material and one fifth of the media needed in the Wave, with less manual effort.
Notably, this process required just 1/3 of the starting material, 1/5 of the media and decreased manual effort through culture duration compared to the Wave. — M. Gohil, D. Hasenmayer, K. M. Haines, A. Jain, L. Lewitt, K. Sporici, A. Dai, D. Negorev, V. E. Gonzalez, I. Kulikovskaya, R. Reynolds, T. Migliaccio, A. L. Brennan, T. A. Colligon, A. L. Russell, Z. Wang, C. June, D. Siegel, B. L. Levine, J. A. Fraietta, J. Jadlowsky, G. Plesa, M. M. Davis, Cytotherapy
Study details
- Authors
- M. Gohil, D. Hasenmayer, K. M. Haines, A. Jain, L. Lewitt, K. Sporici, A. Dai, D. Negorev, V. E. Gonzalez, I. Kulikovskaya, R. Reynolds, T. Migliaccio, A. L. Brennan, T. A. Colligon, A. L. Russell, Z. Wang, C. June, D. Siegel, B. L. Levine, J. A. Fraietta, J. Jadlowsky, G. Plesa, M. M. Davis
- Institution
- Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States
- Journal
- Cytotherapy
- Year
- 2022
- G-Rex® model(s)
- G-Rex®100M
- Cell type(s)
- CAR T Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
Mesothelin CAR T cells were produced from consented patient starting material in disposable G-Rex® culture vessels, in parallel with the conventional Wave bioreactor, within a closed-system lentiviral CAR T manufacturing platform. In the 1L G-Rex®, a seed of 50 million T cells yielded 2-4 billion T cells, with at least 50-fold expansion and viability above 90%.
Explore related
Full citation
Gohil M, Hasenmayer D, Haines KM, et al. A supply chain crisis story: culture bag shortage enforced validation of an alternative expansion system for CAR T cells. Cytotherapy. 2022;24:S160.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.